listofplaytoearncryptogames| Hehuang Pharmaceutical (00013.HK): Data from the sovleplenib ESLIM-01 Phase III study and the hematological malignancies project will be announced at the 2024 European Hematology Association (EHA) Annual Meeting

Gelonghui May 17 丨 Hehuang Pharmaceutical (00013listofplaytoearncryptogames.HK) today announced that it will be held in Madrid, Spain and online from June 13 to June 16, 2024listofplaytoearncryptogamesThe top line and subgroup results of the Phase III study of solopinib ESLIM-01, as well as the latest and updated clinical data on innovative exploratory hematological malignancies HMPL-306, HMPL-760 and tazemetostat were announced at the annual meeting of the European Hematology Association ("EHA").